Cytek Biosciences Inc (CTKB)

Pretax margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	-5,699	-11,911	-16,253	-15,662	-15,709	-15,706	-9,671	-4,477	1,260	-2,400	-2,000	2,668	6,123	13,671	18,318	15,243	14,430
Revenue (ttm)	US$ in thousands	176,629	201,210	197,710	200,786	193,014	183,117	175,594	166,060	164,036	154,594	148,493	138,742	127,950	119,675	110,395	99,123	92,839
Pretax margin		-3.23%	-5.92%	-8.22%	-7.80%	-8.14%	-8.58%	-5.51%	-2.70%	0.77%	-1.55%	-1.35%	1.92%	4.79%	11.42%	16.59%	15.38%	15.54%

December 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-5,699K ÷ $176,629K
= -3.23%

The pretax margin of Cytek Biosciences Inc has shown fluctuations over the analyzed period. It started relatively strong in December 2020 at 15.54% and maintained stability around this level in the following quarters. However, there was a noticeable decline in pretax margin by September 2021 to 11.42%. The margin decreased further to 4.79% by December 2021 and continued on a downward trend in subsequent quarters, reaching negative values by March 2022.

The negative pretax margins persisted until at least December 2024, with fluctuations along the way. By December 2024, the pretax margin had improved slightly to -3.23%.

The downward trend in the pretax margin from 2021 to 2024 indicates potential challenges Cytek Biosciences Inc may be facing in generating profits before taxes. It is essential for the company to closely monitor and manage its expenses and revenue generation to potentially improve its financial performance in the future.